Logo

RPTX

Repare Therapeutics Inc.

RPTX

Repare Therapeutics Inc. • NASDAQ
$2.18 ▼ -1.36% (-0.03)
Market Cap $93.69 M
52w High $4.07
52w Low $0.89
Dividend Yield 0%
P/E -1.28
Volume 128.57K
Outstanding Shares 42.98M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $11.62M ▲ $10.489M ▼ $3.258M ▲ 28.038% ▲ $0.08 ▲ $3.475M ▲
Q2-2025 $250K ▲ $18.03M ▼ $-16.744M ▲ -6.698K% ▼ $-0.39 ▲ $-19.026M ▲
Q1-2025 $0 $26.601M ▼ $-30.043M ▼ 0% $-0.71 ▼ $-28.352M ▼
Q4-2024 $0 $30.202M ▼ $-28.671M ▲ 0% $-0.67 ▲ $-28.077M ▲
Q3-2024 $0 $34.129M $-34.406M 0% $-0.81 $-33.205M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $112.604M ▲ $126.747M ▼ $11.62M ▼ $115.127M ▲
Q2-2025 $109.472M ▼ $130.493M ▼ $20.085M ▲ $110.408M ▼
Q1-2025 $124.228M ▼ $144.023M ▼ $18.926M ▼ $125.097M ▼
Q4-2024 $152.791M ▼ $176.506M ▼ $25.375M ▼ $151.131M ▼
Q3-2024 $179.432M $206.389M $31.43M $174.959M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $3.258M ▲ $2.651M ▲ $2.537M ▲ $30K ▲ $5.169M ▲ $2.651M ▲
Q2-2025 $-16.744M ▲ $-16.342M ▲ $-586K ▼ $0 ▼ $-16.799M ▼ $-16.342M ▲
Q1-2025 $-30.043M ▼ $-29.133M ▼ $28.792M ▼ $79K ▲ $-262K ▼ $-29.133M ▼
Q4-2024 $-28.671M ▲ $-27.324M ▲ $31.586M ▲ $1K ▼ $4.176M ▲ $-27.324M ▲
Q3-2024 $-34.406M $-30.539M $31.08M $166K $721K $-30.539M

Five-Year Company Overview

Income Statement

Income Statement Repare is still essentially a research-stage biotech with only modest collaboration revenue and no established product sales. Its costs are driven mainly by research and clinical development, so operating losses and net losses have been consistent since the IPO. Losses widened as the pipeline ramped up, then narrowed somewhat more recently as the company refocused and cut expenses, but the business remains structurally unprofitable and dependent on external funding or deal income rather than internal cash generation.

Balance Sheet

Balance Sheet The balance sheet shows a clear drawdown of cash and total assets over the last few years as the company funded its R&D efforts. Equity has come down but remains positive, and there is almost no reliance on debt, which keeps financial leverage low. The combination of shrinking cash with a clean but smaller balance sheet underlines that Repare was running down its standalone cash runway and increasingly relying on partnerships, transactions, and now the pending acquisition structure to support future development.

Cash Flow

Cash Flow Cash flow patterns mirror a typical early-stage biotech: persistent cash outflows from operations, reflecting payroll, clinical trials, and platform development. Capital spending has been minimal, so free cash flow is effectively the same as operating cash flow and has been negative in most years. There was a brief period of near break-even operating cash flow when collaboration inflows were stronger, but the recent trend is back to meaningful cash burn, which helps explain the strategic shift, workforce reductions, and emphasis on out-licensing and the acquisition agreement.

Competitive Edge

Competitive Edge Competitively, Repare has carved out a focused niche in synthetic lethality and DNA damage repair, supported by its SNIPRx discovery platform and by several first- or potential best-in-class assets. Partnerships with larger players and institutions offer external validation and access to resources. However, Repare remains a small player in a crowded oncology space with many well-funded competitors working on similar pathways, and now faces the additional complexity of operating under a non-profit acquirer’s umbrella and depending heavily on monetizing its pipeline through deals rather than building a traditional commercial footprint itself.

Innovation and R&D

Innovation and R&D Innovation and R&D are the clear strengths here. The SNIPRx platform provides a systematic way to discover synthetic lethal targets, and the pipeline includes multiple differentiated programs in clinically and commercially attractive mechanisms, such as PKMYT1, ATR, PLK4, and Polθ inhibitors. The company has shown an ability to convert platform findings into partnerships and licensing agreements, which is notable. At the same time, the focus has recently narrowed to a smaller set of lead programs after cost-cutting and strategic realignment, which may help discipline but also concentrates risk in fewer assets whose clinical and partnering outcomes remain uncertain.

Summary

Repare Therapeutics combines strong scientific foundations and a distinctive discovery platform with the financial profile of a typical clinical-stage biotech: limited revenue, steady losses, and ongoing cash burn. The balance sheet is unlevered but has been steadily drawn down, making external capital and deal-making central to its story. The pending acquisition by XenoTherapeutics and the emphasis on licensing and asset sales mark a transition from building an independent oncology company toward maximizing the value of its pipeline and intellectual property under a new structure. Future outcomes will hinge on the clinical data from its core programs, the success and timing of out-licensing transactions, and how effectively the new owner stewards these assets over time.

NEWS

November 20, 2025 · 5:25 PM UTC

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Read more

November 18, 2025 · 7:44 AM UTC

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

Read more

November 17, 2025 · 5:30 PM UTC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)

Read more

November 14, 2025 · 10:59 PM UTC

RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

Read more

November 14, 2025 · 7:56 PM UTC

Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Read more